Friday, July 10, 2026

pharma · Muscle-invasive bladder cancer · Unresectable intrahepatic cholangiocarcinoma

Ningbo Cancer Hospital

Ningbo Cancer Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Muscle-invasive bladder cancer, Unresectable intrahepatic cholangiocarcinoma, Head and neck squamous cell carci

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
120
Drugs
183
Patents
0
Clinical program

Xtandi - soft capsules for Castration resistant prostate c…

Phase 3 · small molecule · Castration resistant prostate cancer patients metastatic to bone.

Xtandi - soft capsules for Castration resistant prostate c… for Castration resistant prostate cancer patients metastatic to bone. is a Phase 3 program (small_molecule) at Ningbo Cancer Hospital with 1 ClinicalTrials.gov record(s).

← All Ningbo Cancer Hospital projects Phase 3 small molecule active

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Ningbo Cancer Hospital
Phase
Phase 3
Modality
small_molecule
Indication
Castration resistant prostate cancer patients metastatic to bone.
Status
active
Trials
1